Venous Thromboembolism Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2032

1.1 The VTE market will experience minimal growth between 2022 and 2032
1.2 Companies are focusing clinical trial development on factor XI inhibitors
1.3 Optimal treatment strategies for patients with cancer or renal impairment are needed
1.4 Abelacimab to contribute moderately to sales during the forecast period
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 7MM forecast methodology
4.5 Epidemiological forecast for venous thromboembolism (VTE) (2022-32)
4.6 Discussion

5.1 Diagnosis and treatment overview
5.2 Key opinion leader insights on disease management

6.1 Overview

7.1 Overview
7.2 Mitigating bleeding risk
7.3 Optimal treatment for cancer patients
7.4 Optimal treatment for patients with renal impairment and renal failure
7.5 Complications associated with parenteral therapies
7.6 Improved education among physicians and patients

8.1 Overview
8.2 Clinical trials design

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.2 US
12.3 5EU
12.4 Japan

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - key opinion leaders interviewed for this report
13.5 Primary research - prescriber survey
13.6 About the Authors

• Contact the Publisher

Table 1: VTE: key metrics in the 7MM
Table 2: Risk factors and comorbidities for VTE
Table 3: Treatment guidelines for VTE
Table 4: VTE market - global drivers and barriers, 2022-32
Table 5: Key events impacting sales for VTE in the US, 2022-32
Table 6: VTE market - drivers and barriers in the US, 2022-32
Table 7: Key events impacting sales for VTE in the 5EU, 2022-32
Table 8: VTE market - drivers and barriers in the 5EU, 2022-32
Table 9: Key events impacting sales for VTE in Japan, 2022-32
Table 10: VTE market - drivers and barriers in Japan, 2022-32
Table 11: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for VTE in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in venous thromboembolism during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that the publisher expects to be licensed for the treatment of venous thromboembolism during the forecast period
Figure 4: 7MM, diagnosed incidence of PE, DVT, and VTE, cases per 100,000 population, both sexes, all ages, 2022
Figure 5: 7MM, sources used to forecast the diagnosed incident cases of PE, DVT, and VTE
Figure 6: 7MM, sources used to forecast the diagnosed incident cases of DVT by anatomical region
Figure 7: 7MM, sources used to forecast the diagnosed incident cases of VTE by provoking risk factor
Figure 8: 7MM, sources used to forecast the diagnosed incident cases of VTE with cancer as a comorbidity
Figure 9: 7MM, sources used to forecast the diagnosed incident cases of VTE with CKD as a comorbidityu
Figure 10: 7MM, sources used to forecast the diagnosed VTE attacks
Figure 11: 7MM, sources used to forecast VTE recurrence after one and 10 years
Figure 12: 7MM, sources used to forecast the number of hospital discharges that meet medically ill criteria and are at risk of VTE
Figure 13: 7MM, sources used and not used to forecast the primary total knee replacements and revisions, and hip replacements.
Figure 14: 7MM, diagnosed incident cases of PE, N, both sexes, all ages, 2022
Figure 15: 7MM, diagnosed incident cases of DVT, N, both sexes, all ages, 2022
Figure 16: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2022
Figure 17: 7MM, diagnosed incident cases of VTE by age, N, both sexes, all ages, 2022
Figure 18: 7MM, diagnosed incident cases of VTE by sex, N, both sexes, all ages, 2022
Figure 19: 7MM, diagnosed incident cases of DVT by anatomical region, N, all ages, 2022
Figure 20: 7MM, diagnosed incident cases of VTE by provoking risk factor, N, both sexes, all ages, 2022
Figure 21: 7MM, first-time recurrent cases of VTE, N, both sexes, all ages, 2022
Figure 22: 7MM, diagnosed incident cases of VTE with cancer as a comorbidity, N, both sexes, all ages, 2022
Figure 23: 7MM, diagnosed incident cases of VTE with CKD as a comorbidity, N, both sexes, 2022 and 2032
Figure 24: 7MM, diagnosed VTE attacks, N, both sexes, all ages, 2022 and 2032
Figure 25: 7MM, number of medically ill hospital discharges at risk for VTE, N, both sexes, =40 years, 2022
Figure 26: 7MM, total number of knee replacements, N, both sexes, =15 years, 2022 and 2032
Figure 27: 7MM, total number of hip replacements, N, both sexes, =15 years, 2022 and 2032
Figure 28: Treatment algotrithm for VTE
Figure 29: Unmet needs and opportunities in VTE
Figure 30: Overview of the development pipeline in VTE
Figure 31: Key late-stage trials for the promising pipeline agents that the publisher expects be licensed for VTE in the 7MM during the forecast period
Figure 32: Competitive assessment of the late-stage pipeline agents that the publisher expects to be licensed for the treatment of VTE during the forecast period
Figure 33: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC: NOACs
Figure 34: Analysis of the company portfolio gap in VTE during the forecast period
Figure 35: Deal-making trends, number of deals, 2018-22
Figure 36: Deal-making trends, value of deals, 2018-22
Figure 37: 7MM sales forecast by country for VTE in 2022 and 2032
Figure 38: Sales forecast by class for VTE treatment in the US in 2022 and 2032
Figure 39: Sales forecast by class for VTE primary prophylaxis in the US in 2022 and 2032
Figure 40: Sales forecast by country for VTE treatment and primary prophylaxis in the 5EU in 2022 and 2032
Figure 41: Sales forecast by class for VTE treatment and primary prophylaxis in the 5EU in 2022 and 2032
Figure 42: Sales forecast by class for VTE treatment in Japan in 2022 and 2032
Figure 43: Sales forecast by class for VTE primary prophylaxis in Japan in 2022 and 2032